Enterohemorrhagic Escherichia coli O157: H7 survival in an In vitro model of the human large intestine and interactions with probiotic yeasts and resident microbiota

Applied and Environmental Microbiology

Volumn 79, Issue 3, 2013, Pages 1058-1064

  Thévenot, Jonathan ^a   Etienne Mesmin, Lucie ^a   Denis, Sylvain ^a   Chalancon, Sandrine ^a   Alric, Monique ^a   Livrelli, Valérie ^a,b   Blanquet Diot, Stéphanie ^a  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENTEROHEMORRHAGIC ESCHERICHIA COLI; IN-VITRO; LARGE INTESTINE; MICROBIOTAS; PROBIOTIC STRAIN; PROBIOTICS;

ESCHERICHIA COLI;

YEAST;

PROBIOTIC AGENT;

ACETATE (ESTER); BIOTA; MICROBIOLOGY; PATHOGEN; PROBIOTICS; SURVIVAL; YEAST;

ARTICLE; BIOREACTOR; ESCHERICHIA COLI O157; HUMAN; LARGE INTESTINE; METAGENOME; MICROBIAL VIABILITY; MICROBIOLOGY; ORGANISMAL INTERACTION; PHYSIOLOGY; SACCHAROMYCES CEREVISIAE; THEORETICAL MODEL;

BIOREACTORS; ESCHERICHIA COLI O157; HUMANS; INTESTINE, LARGE; METAGENOME; MICROBIAL INTERACTIONS; MICROBIAL VIABILITY; MODELS, THEORETICAL; PROBIOTICS; SACCHAROMYCES CEREVISIAE;

EID: 84873825736     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.03303-12     Document Type: Article

References (55)

1. Pennington H. 2010. Escherichia coli O157. Lancet 376:1428-1435.
2. Frank C, Werber D, Cramer JP, Askar M, Faber M, an der Heiden M, Bernard H, Fruth A, Prager R, Spode A, Wadl M, Zoufaly A, Jordan S, Kemper MJ, Follin P, Muller L, King LA, Rosner B, Buchholz U, Stark K, Krause G. 2011. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N. Engl. J. Med. 365:1771-1780.
3. King LA, Nogareda F, Weill FX, Mariani-Kurkdjian P, Loukiadis E, Gault G, Jourdan-DaSilva N, Bingen E, Mace M, Thevenot D, Ong N, Castor C, Noel H, Van Cauteren D, Charron M, Vaillant V, Aldabe B, Goulet V, Delmas G, Couturier E, Le Strat Y, Combe C, Delmas Y, Terrier F, Vendrely B, Rolland P, de Valk H. 2012. Outbreak of Shiga toxin-producing Escherichia coli O104:H4 associated with organic fenugreek sprouts, France, June 2011. Clin. Infect. Dis. 54:1588-1594.
4. Chong Y, Fitzhenry R, Heuschkel R, Torrente F, Frankel G, PhillipsAD. 2007. Human intestinal tissue tropism in Escherichia coli O157: H7-initial colonization of terminal ileum and Peyer's patches and minimal colonic adhesion ex vivo. Microbiology 153:794-802.
5. Shigeno T, Akamatsu T, Fujimori K, Nakatsuji Y, Nagata A. 2002. The clinical significance of colonoscopy in hemorrhagic colitis due to enterohemorrhagic Escherichia coli O157:H7 infection. Endoscopy 34:311-314.
6. Naylor SW, Gally DL, Low JC. 2005. Enterohaemorrhagic E. coli in veterinary medicine. Int. J. Med. Microbiol. 295:419-441.
7. Guerra A, Etienne-Mesmin L, Livrelli V, Denis S, Blanquet-Diot S, Alric M. 2012. Relevance and challenges in modeling human gastric and small intestinal digestion. Trends Biotechnol. 30:591-600.
8. Payne AN, Zihler A, Chassard C, Lacroix C. 2012. Advances and perspectives in in vitro human gut fermentation modeling. Trends Biotechnol. 30:17-25.
9. Etienne-Mesmin L, Livrelli V, Privat M, Denis S, Cardot JM, Alric M, Blanquet-Diot S. 2011. Effect of a new probiotic Saccharomyces cerevisiae strain on survival of Escherichia coli O157:H7 in a dynamic gastrointestinal model. Appl. Environ. Microbiol. 77:1127-1131.
10. de Sablet T, Chassard C, Bernalier-Donadille A, Vareille M, Gobert AP, Martin C. 2009. Human microbiota-secreted factors inhibit Shiga toxin synthesis by enterohemorrhagic Escherichia coli O157:H7. Infect. Immun. 77:783-790.
11. Toshima H, Yoshimura A, Arikawa K, Hidaka A, Ogasawara J, Hase A, Masaki H, Nishikawa Y. 2007. Enhancement of Shiga toxin production in enterohemorrhagic Escherichia coli serotype O157:H7 by DNase colicins. Appl. Environ. Microbiol. 73:7582-7588.
12. Kendall MM, Gruber CC, Parker CT, Sperandio V. 2012. Ethanolamine controls expression of genes encoding components involved in interkingdom signaling and virulence in enterohemorrhagic Escherichia coli O157: H7. mBio 3:e00050-12. doi:10.1128/mBio.00050-12.
13. Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, Bremer JP, Brunkhorst R, Busch V, Dengler R, Deuschl G, Fellermann K, Fickenscher H, Gerigk C, Goettsche A, Greeve J, Hafer C, Hagenmuller F, Haller H, Herget-Rosenthal S, Hertenstein B, Hofmann C, Lang M, Kielstein JT, Klostermeier UC, Knobloch J, Kuehbacher M, Kunzendorf U, Lehnert H, Manns MP, Menne TF, Meyer TN, Michael C, Munte T, Neumann-Grutzeck C, Nuernberger J, Pavenstaedt H, Ramazan L, Renders L, Repenthin J, Ries W, Rohr A, Rump LC, Samuelsson O, Sayk F, Schmidt BM, Schnatter S, Schocklmann H, Schreiber S, von Seydewitz CU, Steinhoff J, Stracke S, Suerbaum S, van de Loo A, Vischedyk M, Weissenborn K, Wellhoner P, Wiesner M, Zeissig S, Buning J, Schiffer M, Kuehbacher T. 2012. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 345:e4565. doi:10.1136/bmj.e4565.
14. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. 2000. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N. Engl. J. Med. 342:1930-1936.
15. FAO/WHO. 2002. Report of a joint FAO/WHO working group on drafting guidelines for the evaluation of probiotics in food. Food and Agriculture Organization of the United Nations and World Health Organization, London, Ontario, Canada.
16. Preidis GA, Hill C, Guerrant RL, Ramakrishna BS, Tannock GW, Versalovic J. 2011. Probiotics, enteric and diarrheal diseases, and global health. Gastroenterology 140:8-14.
17. Bach SJ, McAllister TA, Veira DM, Gannon VPJ, Holley RA. 2003. Effects of a Saccharomyces cerevisiae feed supplement on Escherichia coli O157:H7 in ruminal fluid in vitro. Anim. Feed Sci. Technol. 104:179-189.
18. Dahan S, Dalmasso G, Imbert V, Peyron JF, Rampal P, Czerucka D. 2003. Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells. Infect. Immun. 71: 766-773.
19. Dalmasso G, Loubat A, Dahan S, Calle G, Rampal P, Czerucka D. 2006. Saccharomyces boulardii prevents TNF-alpha-induced apoptosis in EHEC-infected T84 cells. Res. Microbiol. 157:456-465.
20. Blanquet-Diot S, Denis S, Chalancon S, Chaira F, Cardot JM, Alric M. 2012. Use of artificial digestive systems to investigate the biopharmaceutical factors influencing the survival of probiotic yeast during gastrointestinal transit in humans. Pharm. Res. 29:1444-1453.
21. Gobert AP, Vareille M, Glasser AL, Hindre T, de Sablet T, Martin C. 2007. Shiga toxin produced by enterohemorrhagic Escherichia coli inhibits PI3K/NF-kappaB signaling pathway in globotriaosylceramide-3-negative human intestinal epithelial cells. J. Immunol. 178:8168-8174.
22. McFarland LV. 2010. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J. Gastroenterol. 16:2202-2222.
23. Danckwerts PV. 1953. Continuous flow systems: distribution of residence times. Chem. Eng. Sci. 2:1-13.
24. Yu Z, Morrison M. 2004. Improved extraction of PCR-quality community DNA from digesta and fecal samples. Biotechniques 36:808-812.
25. Yu Y, Lee C, Kim J, Hwang S. 2005. Group-specific primer and probe sets to detect methanogenic communities using quantitative real-time polymerase chain reaction. Biotechnol. Bioeng. 89:670-679.
26. Bacchetti De Gregoris T, Aldred N, Clare AS, Burgess JG. 2011. Improvement of phylum-and class-specific primers for real-time PCR quantification of bacterial taxa. J. Microbiol. Methods 86:351-356.
27. Bartosch S, Fite A, Macfarlane GT, McMurdo ME. 2004. Characterization of bacterial communities in feces from healthy elderly volunteers and hospitalized elderly patients by using real-time PCR and effects of antibiotic treatment on the fecal microbiota. Appl. Environ. Microbiol. 70: 3575-3581.
28. Furet JP, Firmesse O, Gourmelon M, Bridonneau C, Tap J, Mondot S, Dore J, Corthier G. 2009. Comparative assessment of human and farm animal faecal microbiota using real-time quantitative PCR. FEMS Microbiol. Ecol. 68:351-362.
29. Huijsdens XW, Linskens RK, Mak M, Meuwissen SG, Vandenbroucke-Grauls CM, Savelkoul PH. 2002. Quantification of bacteria adherent to gastrointestinal mucosa by real-time PCR. J. Clin. Microbiol. 40:4423-4427.
30. Gerard-Champod M, Blanquet-Diot S, Cardot JM, Bravo D, Alric M. 2010. Development and validation of a continuous in vitro system reproducing some biotic and abiotic factors of the veal calf intestine. Appl. Environ. Microbiol. 76:5592-5600.
31. Lievin-Le Moal V, Servin AL. 2006. The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota. Clin. Microbiol. Rev. 19:315-337.
32. Eberhart LJ, Deringer JR, Brayton KA, Sawant AA, Besser TE, Call DR. 2012. Characterization of a novel microcin that kills enterohemorrhagic Escherichia coli O157:H7 and O26. Appl. Environ. Microbiol. 78:6592-6599.
33. Schamberger GP, Diez-Gonzalez F. 2005. Assessment of resistance to colicinogenic Escherichia coli by E. coli O157:H7 strains. J. Appl. Microbiol. 98:245-252.
34. Etienne-Mesmin L, Chassaing B, Sauvanet P, Denizot J, Blanquet-Diot S, Darfeuille-Michaud A, Pradel N, Livrelli V. 2011. Interactions with M cells and macrophages as key steps in the pathogenesis of enterohemorragic Escherichia coli infections. PLoS One 6:e23594. doi:10.1371/journal .pone.0023594.
35. Nakanishi N, Tashiro K, Kuhara S, Hayashi T, Sugimoto N, Tobe T. 2009. Regulation of virulence by butyrate sensing in enterohaemorrhagic Escherichia coli. Microbiology 155:521-530.
36. Edwards-Ingram L, Gitsham P, Burton N, Warhurst G, Clarke I, Hoyle D, Oliver SG, Stateva L. 2007. Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae. Appl. Environ. Microbiol. 73:2458-2467.
37. Fietto JL, Araujo RS, Valadao FN, Fietto LG, Brandao RL, Neves MJ, Gomes FC, Nicoli JR, Castro IM. 2004. Molecular and physiological comparisons between Saccharomyces cerevisiae and Saccharomyces boulardii. Can. J. Microbiol. 50:615-621.
38. Klein SM, Elmer GW, McFarland LV, Surawicz CM, Levy RH. 1993. Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers. Pharm. Res. 10:1615-1619.
39. Pecquet S, Guillaumin D, Tancrede C, Andremont A. 1991. Kinetics of Saccharomyces cerevisiae elimination from the intestines of human volunteers and effect of this yeast on resistance to microbial colonization in gnotobiotic mice. Appl. Environ. Microbiol. 57:3049-3051.
40. Chiou RY, Phillips RD, Zhao P, Doyle MP, Beuchat LR. 2004. Ethanolmediated variations in cellular fatty acid composition and protein profiles of two genotypically different strains of Escherichia coli O157:H7. Appl. Environ. Microbiol. 70:2204-2210.
41. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims S, Torrents D, Ugarte E, Zoetendal EG, Wang J, Guarner F, Pedersen O, de Vos WM, Brunak S, Dore J, Antolin M, Artiguenave F,Blottiere HM, Almeida M, Brechot C, Cara C, Chervaux C, Cultrone A, Delorme C, Denariaz G, Dervyn R, Foerstner KU, Friss C, van de Guchte M, Guedon E, Haimet F, Huber W, van Hylckama-Vlieg J, Jamet A, Juste C, Kaci G, Knol J, Lakhdari O, Layec S, Le Roux K, Maguin E, Merieux A, Melo Minardi R, M'Rini C, Muller J, Oozeer R, Parkhill J, Renault P, Rescigno M, Sanchez N, Sunagawa S, Torrejon A, Turner K, Vandemeulebrouck G, Varela E, Winogradsky Y, Zeller G, Weissenbach J, Ehrlich SD, Bork P. 2011. Enterotypes of the human gut microbiome. Nature 473:174-180.
42. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA. 2005. Diversity of the human intestinal microbial flora. Science 308:1635-1638.
43. Finegold SM, Attebery HR, Sutter VL. 1974. Effect of diet on human fecal flora: comparison of Japanese and American diets. Am. J. Clin. Nutr. 27: 1456-1469.
44. Marteau P, Pochart P, Dore J, Bera-Maillet C, Bernalier A, Corthier G. 2001. Comparative study of bacterial groups within the human cecal and fecal microbiota. Appl. Environ. Microbiol. 67:4939-4942.
45. Marzorati M, Verhelst A, Luta G, Sinnott R, Verstraete W, Van de Wiele T, Possemiers S. 2010. In vitro modulation of the human gastrointestinal microbial community by plant-derived polysaccharide-rich dietary supplements. Int. J. Food Microbiol. 139:168-176.
46. Sannasiddappa TH, Costabile A, Gibson GR, Clarke SR. 2011. The influence of Staphylococcus aureus on gut microbial ecology in an in vitro continuous culture human colonic model system. PLoS One 6:e23227. doi:10.1371/journal.pone.0023227.
47. Gamage SD, Strasser JE, Chalk CL, Weiss AA. 2003. Nonpathogenic Escherichia coli can contribute to the production of Shiga toxin. Infect. Immun. 71:3107-3115.
48. Swidsinski A, Loening-Baucke V, Verstraelen H, Osowska S, Doerffel Y.2008. Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology 135:568-579.
49. Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. 1987. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28:1221-1227.
50. Topping DL, Clifton PM. 2001. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol. Rev. 81:1031-1064.
51. Schneider SM, Girard-Pipau F, Filippi J, Hebuterne X, Moyse D, Hinojosa GC, Pompei A, Rampal P. 2005. Effects of Saccharomyces boulardii on fecal short-chain fatty acids and microflora in patients on long-term total enteral nutrition. World J. Gastroenterol. 11:6165-6169.
52. Asahara T, Shimizu K, Nomoto K, Hamabata T, Ozawa A, Takeda Y. 2004. Probiotic bifidobacteria protect mice from lethal infection with Shiga toxin-producing Escherichia coli O157:H7. Infect. Immun. 72: 2240-2247.
53. Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K, Tobe T, Clarke JM, Topping DL, Suzuki T, Taylor TD, Itoh K, Kikuchi J, Morita H, Hattori M, Ohno H. 2011. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469: 543-547.
54. Hatanaka M, Nakamura Y, Maathuis AJ, Venema K, Murota I, Yamamoto N. 2012. Influence of Bacillus subtilis C-3102 on microbiota in a dynamic in vitro model of the gastrointestinal tract simulating human conditions. Benef. Microbes 3:229-236.
55. Possemiers S, Marzorati M, Verstraete W, Van de Wiele T. 2010. Bacteria and chocolate: a successful combination for probiotic delivery. Int. J. Food Microbiol. 141:97-103.